2016-2018 Drug Discovery for Neurodegeneration Conferences

2016-2018 神经退行性疾病药物发现会议

• 批准号: 9051961
• 负责人: Howard M. Fillit
• 金额: $ 7万
• 依托单位: ALZHEIMER'S DRUG DISCOVERY FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-30 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9051961
• 关键词: Academia; Address; Advanced Development; Advisory Committees; Aging; Alzheimer' s Disease; Area; Basic Science; Biologic Development; Case Study; Chemistry; Clinical; Collaborations; Communities; Development; Discipline; Disease; District of Columbia; Drug Industry; Drug Targeting; Evaluation; Fostering; Foundations; Funding; Goals; Grant; Industry; Innovative Therapy; Internet; Knowledge; Lead; Learning; Marketing; Mentors; Minority; Multiple Sclerosis; NIH Program Announcements; Nerve Degeneration; Neurodegenerative Disorders; Outcome; Parkinson Disease; Participant; Pharmaceutical Preparations; Pharmacology; Preclinical Drug Development; Prevention; Process; Research; Research Contracts; Research Personnel; Resource Sharing; Resources; Schedule; Science; Scientist; Staging; Surveys; Testing; Time; Training; Translating; Translational Research; U-Series Cooperative Agreements; United States National Institutes of Health; Woman; abstracting; acronyms; commercialization; drug development; drug discovery; effective therapy; graduate student; meetings; nervous system disorder; next generation; novel; novel therapeutics; outreach; posters; pre-clinical research; prevent; programs; public health relevance; public-private partnership; quantum; skills; small molecule; symposium; therapy development; trend; web site

 DESCRIPTION (provided by applicant): There is a well-documented knowledge and resource gap in translating basic research into novel therapeutics. Outside of the pharmaceutical industry, there are very few opportunities for the next generation of scientific leaders to learn about the drug discovery and development process in general, and particularly for neurodegenerative diseases. To meet this need, the Alzheimer's Drug Discovery Foundation (ADDF) developed the annual Drug Discovery for Neurodegeneration (DDND) conference, which has reached 1,252 participants since its inception in 2007. The ADDF requests a U13 Cooperative Agreement conference grant for three years of support for its DDND conference, scheduled for March 2016 in Miami, FL, March 2017 in San Diego, CA, and March 2018 in the Washington, D.C. metro area. The goals of these didactic conferences are clearly consistent with the initiatives set forth at the NIH's 2012 and 2015 Alzheimer's Disease Research Summit: to bridge the knowledge gap in drug discovery and neurodegenerative disease; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; and to provide networking opportunities for these scientists to exchange ideas and resources. These conferences will provide participants with fundamental knowledge and resources on developing new drugs to treat and prevent neurodegenerative diseases, and will address the challenges associated with the following sub-topics: (1) Embarking on a Drug Discovery Campaign; (2) Starting at the End: The Pharmacology-Chemistry Interface in Preclinical Drug Development; (3) Drug Discovery: From Lead to Clinical Candidate; (4) Strategies for CNS Targets: Case Study Examples; and (5) Commercialization Strategies: Developing Science into Products. Discussions will include relevant examples focused on small molecule and biologic development for Alzheimer's and related neurodegenerative diseases. Sessions will consist of 30 minute presentations with ample time for Q&A, and the program will include sessions for networking, partnering/mentoring, and posters presented by young investigators. With respect to public-private partnerships, the ADDF will invite 22 internationally recognized scientists from academia, industry and the NIH to serve as chairs or speakers. We have assembled a Scientific Advisory Committee that has agreed to participate for the next three years to assist in the development of the conferences. It is anticipated that these conferences will serve 150 scientists annually from diverse backgrounds, including women, minorities, young/junior investigators and graduate students.

 描述（由申请人提供）：在将基础研究转化为新型疗法方面存在有据可查的知识和资源差距。在制药行业之外，下一代科学领导者很少有机会了解一般的药物发现和开发过程，特别是神经退行性疾病的药物发现和开发过程。为了满足这一需求，阿尔茨海默病药物发现基金会 (ADDF) 举办了年度神经退行性疾病药物发现 (DDND) 会议，自 2007 年成立以来，已有 1,252 名与会者参加。ADDF 请求 U13 合作协议会议拨款，为​​其 DDND 会议提供三年支持，会议定于 2016 年 3 月在佛罗里达州迈阿密举行，2017 年 3 月在加利福尼亚州圣地亚哥举行，2018 年 3 月在加利福尼亚州举行。 华盛顿特区都会区。这些教学会议的目标显然与 NIH 2012 年和 2015 年阿尔茨海默病研究峰会上提出的倡议一致：弥合药物发现和神经退行性疾病方面的知识差距；汇集跨学科科学家，激发结合技能和学科的新方法；并为这些科学家提供交流想法和资源的交流机会。这些会议将为与会者提供开发新药治疗和预防神经退行性疾病的基础知识和资源，并将解决与以下子主题相关的挑战：（1）开展药物发现活动； （2）从终点开始：临床前药物开发中的药理学-化学界面； (3) 药物发现：从先导药物到临床候选药物； (4) CNS 目标策略：案例研究示例； (5) 商业化策略：将科学发展为产品。讨论将包括针对阿尔茨海默氏症和相关神经退行性疾病的小分子和生物制剂开发的相关示例。会议将包括 30 分钟的演讲和充足的问答时间，该计划将包括网络、合作/指导以及年轻研究人员展示的海报会议。在公私合作方面，ADDF将邀请来自学术界、工业界和NIH的22名国际知名科学家担任主席或发言人。我们组建了一个科学咨询委员会，同意在未来三年内参与会议，以协助会议的发展。预计这些会议每年将为来自不同背景的 150 名科学家提供服务，包括女性、少数族裔、年轻/初级研究人员和研究生。